Schellenberg Wittmer acted as Swiss counsel to SPRIM Global Investments (SGI), a leading health sciences venture capital firm, in its capital commitment of USD 4.5 million in favor of Spexis AG, a clinical-stage and biopharmaceutical company listed on the SIX Swiss Exchange, to enable initiation of ColiFin® Phase 3 study.